An official website of the United States government
Dementia and mild cognitive impairment are vastly underdiagnosed. Identifying cognitive issues early is the first step toward helping older adults get the care they deserve while also lowering the cost of care.
Neurotrack’s Cognitive Health Suite can meet the needs of providers caring for the 58 million U.S. adults who are age 65 or older. The company’s tools are currently in use in a variety of U.S. health systems and care delivery organizations, where teams are saving up to 10 minutes per patient using streamlined solutions for cognitive screening. These tools offer better sensitivity and specificity than traditional pen-and-paper assessments. They are also more efficient, score instantly and objectively, integrate with electronic health records, and require minimal oversight, enabling health care teams to work at the top of their license.
Company Milestones
Learn more about Neurotrack's milestones from 2012 to 2024 below.
Scientific and Clinical
- 2012: Identified a computerized task that predicts mild cognitive impairment and Alzheimer’s disease, as published in the American Journal of Alzheimer’s Disease and Other Dementias
- 2017: Demonstrated the ability to use embedded device cameras for eye tracking, as published in Frontiers in Neuroscience
- 2018: Demonstrated improved cognition after one year in Neurotrack’s cognitive health intervention program, as published in JMIR Aging
- 2019: Demonstrated effectiveness in offering a digital cognitive assessment and multidomain intervention program to a Japanese population, as published in JMIR mHealth and uHealth
- 2022: Verified the reliability of Neurotrack’s battery in remote, asynchronous settings, as published in JMIR Formative Research
Business
- 2012: Neurotrack founded
- 2016: Announced release of the Neurotrack eye-tracking test
- 2018: Offered cognitive testing solutions to the Japanese insurance market for long-term care
- 2020: Received a $3 million NIA SBIR grant to further validate the intervention program
- 2020: Received Food and Drug Administration (FDA) registration as a Class II medical device
- 2021: Received a $750,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF) to evaluate the platform’s ability to monitor cognition longitudinally
- 2022: Launched long-term care and underwriting solutions in the United States; shifted focus to the U.S. health care market
- 2023: Scaled and deployed an in-clinic screening tool with various health delivery organizations, integrated into electronic health records
- 2024: Growing health system business; solutions being used by partners in virtual and in-home care
Financial Overview
Neurotrack has raised more than $62.8 million in venture investment and $4.3 million in grant funding from NIA, ADDF, and the Georgia Research Alliance. The company is now in market, with an aim to become self-sustaining in the near term.
Intellectual Property
Neurotrack has published 25 peer-reviewed papers, holds 11 patents on its proprietary technology, and is registered as an FDA Class II medical device.
Commercialization Strategy
Neurotrack works with a variety of health care delivery organizations, including leading health systems, virtual care providers, major in-home care companies, and participating providers in the new Centers for Medicare & Medicaid Services GUIDE Model.
Company Details
Redwood City, California
Industry: Digital Health and Sensing Technologies
Management Team:
- Elli Kaplan, CEO and Cofounder
- Shawn Lemerise, Chief Growth Officer
- Jordan Glenn, Chief Science Officer
- Jeff Magnusson, Chief Technology Officer
Point of Contact:
Elli Kaplan
Email elli@neurotrack.com